167 related articles for article (PubMed ID: 24307987)
21. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Saridaki Z; Androulakis N; Vardakis N; Vamvakas L; Kabouraki E; Kalbakis K; Hatzidaki D; Voutsina A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2012 Dec; 107(12):1932-7. PubMed ID: 23169296
[TBL] [Abstract][Full Text] [Related]
22. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
26. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
27. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.
Cheng K; Chen Y; Li LH; Liu JY
J Cancer Res Ther; 2013; 9(4):727-9. PubMed ID: 24518728
[TBL] [Abstract][Full Text] [Related]
28. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
29. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
30. Colon cancer, version 3.2014.
Benson AB; Venook AP; Bekaii-Saab T; Chan E; Chen YJ; Cooper HS; Engstrom PF; Enzinger PC; Fenton MJ; Fuchs CS; Grem JL; Hunt S; Kamel A; Leong LA; Lin E; Messersmith W; Mulcahy MF; Murphy JD; Nurkin S; Rohren E; Ryan DP; Saltz L; Sharma S; Shibata D; Skibber JM; Sofocleous CT; Stoffel EM; Stotsky-Himelfarb E; Willett CG; Gregory KM; Freedman-Cass DA;
J Natl Compr Canc Netw; 2014 Jul; 12(7):1028-59. PubMed ID: 24994923
[TBL] [Abstract][Full Text] [Related]
31. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
32. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
33. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
Bruera G; Cannita K; Tessitore A; Russo A; Alesse E; Ficorella C; Ricevuto E
Crit Rev Oncol Hematol; 2015 Mar; 93(3):190-202. PubMed ID: 25459669
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Zhu LM; Zhao YZ; Ju HX; Liu LY; Chen L; Liu BX; Xu Q; Luo C; Ying JE; Yang YS; Zhong HJ
Asian Pac J Cancer Prev; 2014; 15(16):6559-64. PubMed ID: 25169487
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
36. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
37. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
39. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
